Deerfield Management Company, L.P. (Series C) Novo Cure LTD Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Novo Cure LTD stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 650,119 shares of NVCR stock, worth $11.9 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
650,119Holding current value
$11.9 Million% of portfolio
0.29%Shares
1 transactions
Others Institutions Holding NVCR
# of Institutions
266Shares Held
79.4MCall Options Held
970KPut Options Held
118K-
Black Rock Inc. New York, NY12.1MShares$223 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$207 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA8.95MShares$164 Million0.03% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT5.52MShares$101 Million8.14% of portfolio
-
Capital World Investors Los Angeles, CA5.22MShares$95.9 Million0.02% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $1.93B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...